March 2022: We have reviewed the evidence and made new recommendations on continuous glucose monitoring for children and young people with type 1 diabetes. These recommendations are marked .
We have also made one change without an evidence review: In the section on monitoring capillary blood glucose, wording has been added to the heading and recommendations to make it clear that recommendations apply to children and young people who are using capillary blood glucose monitoring rather than CGM. These recommendations are marked [2015, amended 2022].
Recommendations marked , , [2004, amended 2015] or  last had an evidence review in that year. In some cases, minor changes have been made to the wording to bring the language and style up to date, without changing the meaning.
December 2020: We have reviewed the evidence and made new recommendations on fluid therapy for children and young people with diabetic ketoacidosis. These recommendations are marked .
We have also amended recommendations 1.2.4, 1.2.125 and 1.3.52 without an evidence review. This is to provide clarity about eye examinations and to bring them in line with the diabetic eye screening programme. These recommendations are marked [2015, amended 2020].
We have also amended recommendation 1.2.1 to highlight an MHRA safety update reminding patients to rotate insulin injection sites within the same body region to avoid cutaneous amyloidosis.